In contrast with a prevailing view consisting in CD47:SIRPα targeting for cancer cure, a crucial role for TSP-1 has recently emerged in the context of immunomodulation, as TSP-1 binding to CD47 was found to directly control adaptive immunity via inhibiting T-cell differentiation, activation and proliferation [9,10], and reduce macrophage activation [12]. The gene discussed is SIRPA; the disease is cancer.